Literature DB >> 19571552

Objective acoustic-phonetic speech analysis in patients treated for oral or oropharyngeal cancer.

Marieke J de Bruijn1, Louis ten Bosch, Dirk J Kuik, Hugo Quené, Johannes A Langendijk, C René Leemans, Irma M Verdonck-de Leeuw.   

Abstract

OBJECTIVE: Speech impairment often occurs in patients after treatment for head and neck cancer. New treatment modalities such as surgical reconstruction or (chemo)radiation techniques aim at sparing anatomical structures that are correlated with speech and swallowing. In randomized trials investigating efficacy of various treatment modalities or speech rehabilitation, objective speech analysis techniques may add to improve speech outcome assessment. The goal of the present study is to investigate the role of objective acoustic-phonetic analyses in a multidimensional speech assessment protocol. PATIENTS AND METHODS: Speech recordings of 51 patients (6 months after reconstructive surgery and postoperative radiotherapy for oral or oropharyngeal cancer) and of 18 control speakers were subjectively evaluated regarding intelligibility, nasal resonance, articulation, and patient-reported speech outcome (speech subscale of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Head and Neck 35 module). Acoustic-phonetic analyses were performed to calculate formant values of the vowels /a, i, u/, vowel space, air pressure release of /k/ and spectral slope of /x/.
RESULTS: Intelligibility, articulation, and nasal resonance were best predicted by vowel space and /k/. Within patients, /k/ and /x/ differentiated tumor site and stage. Various objective speech parameters were related to speech problems as reported by patients.
CONCLUSION: Objective acoustic-phonetic analysis of speech of patients is feasible and contributes to further development of a speech assessment protocol. Copyright 2009 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2009        PMID: 19571552     DOI: 10.1159/000219953

Source DB:  PubMed          Journal:  Folia Phoniatr Logop        ISSN: 1021-7762            Impact factor:   0.849


  8 in total

Review 1.  What Acoustic Studies Tell Us About Vowels in Developing and Disordered Speech.

Authors:  Ray D Kent; Carrie Rountrey
Journal:  Am J Speech Lang Pathol       Date:  2020-07-06       Impact factor: 2.408

2.  Validity of patient-reported swallowing and speech outcomes in relation to objectively measured oral function among patients treated for oral or oropharyngeal cancer.

Authors:  R N P M Rinkel; I M Verdonck-de Leeuw; R de Bree; N K Aaronson; C R Leemans
Journal:  Dysphagia       Date:  2015-01-28       Impact factor: 3.438

3.  Effects of Aging on Vocal Fundamental Frequency and Vowel Formants in Men and Women.

Authors:  Julie Traub Eichhorn; Raymond D Kent; Diane Austin; Houri K Vorperian
Journal:  J Voice       Date:  2017-08-30       Impact factor: 2.009

4.  Gender difference in speech intelligibility using speech intelligibility tests and acoustic analyses.

Authors:  Ho-Beom Kwon
Journal:  J Adv Prosthodont       Date:  2010-09-30       Impact factor: 1.904

Review 5.  Outcome measurements after oral cancer treatment: speech and speech-related aspects--an overview.

Authors:  M Schuster; F Stelzle
Journal:  Oral Maxillofac Surg       Date:  2012-08-03

Review 6.  Static measurements of vowel formant frequencies and bandwidths: A review.

Authors:  Raymond D Kent; Houri K Vorperian
Journal:  J Commun Disord       Date:  2018-06-01       Impact factor: 2.288

7.  [Functional results after soft palate reconstruction in oropharyngeal cancer patients].

Authors:  M Herzog; D Grafmans; S K Plontke; S Bartel; S Plößl
Journal:  HNO       Date:  2021-02       Impact factor: 1.284

8.  Photobiomodulation therapy in management of cancer therapy-induced side effects: WALT position paper 2022.

Authors:  Jolien Robijns; Raj G Nair; Joy Lodewijckx; Praveen Arany; Andrei Barasch; Jan M Bjordal; Paolo Bossi; Anne Chilles; Patricia M Corby; Joel B Epstein; Sharon Elad; Reza Fekrazad; Eduardo Rodrigues Fregnani; Marie-Thérèse Genot; Ana M C Ibarra; Michael R Hamblin; Vladimir Heiskanen; Ken Hu; Jean Klastersky; Rajesh Lalla; Sofia Latifian; Arun Maiya; Jeroen Mebis; Cesar A Migliorati; Dan M J Milstein; Barbara Murphy; Judith E Raber-Durlacher; Hendrik J Roseboom; Stephen Sonis; Nathaniel Treister; Yehuda Zadik; René-Jean Bensadoun
Journal:  Front Oncol       Date:  2022-08-30       Impact factor: 5.738

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.